GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
- GeoVax Labs NASDAQ: GOVX is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential appreciation in. Working on a treatment for a disease that the World Health Organization (WHO) just declared a “public health emergency," investors should be informed about the company.
- 08/20/2024
|
GeoVax's stock slides 20% after company raises $8.5 million in stock sale
- GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale of 1.7 million shares priced at $5 each in a registered direct offering. The stock closed Monday up 1.7% at $7.15, after a rollercoaster session that saw it soar more than 40% at its peak, on excitement about its work to develop an mpox vaccine.
- 08/20/2024
|
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
- ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,700,000 shares of the Company's common stock (or common stock equivalents) at a price of $5.00 per share in a registered direct offering priced above-the-market under Nasdaq rules.
- 08/20/2024
|
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
- Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
- 08/19/2024
|
GeoVax's stock soars 54% to lead rally in companies developing mpox treatments
- GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.
- 08/19/2024
|
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
- Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
- 08/15/2024
|
GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript
- GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer Conference Call Participants Robert LeBoyer - Noble Capital Markets Jason Kolbert - EF Hutton Jeff Kraws - Crystal Research Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2024 Corporate Update Call. My name is Alex and I will facilitate today's call.
- 08/10/2024
|
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
- Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI).
- 08/08/2024
|
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
- Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study
- 08/06/2024
|
Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
- Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor
- 07/31/2024
|
GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst
- Geovax Labs (NASDAQ: GOVX ) stock is jumping on Tuesday as investors in GOVX prepare for a catalyst on July 18. That's when Geovax Labs will hold a presentation at the Emerging Growth Conference.
- 07/16/2024
|
Why Is GeoVax (GOVX) Stock Up 110% Today?
- Biotechnology specialist GeoVax (NASDAQ: GOVX ) — which focuses on developing immunotherapies and vaccines against cancers and infectious diseases — just announced a partnership with global clinical research organization Allucent. The main purpose behind the agreement is to conduct a Phase 2b clinical trial of GeoVax's next-generation Covid-19 vaccine.
- 06/27/2024
|
GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript
- GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Robert LeBoyer - Noble Capital Markets Operator Good afternoon, and welcome everyone to the GeoVax First Quarter 2024 Corporate Update Call. My name is Mark, and I will facilitate today's call.
- 05/14/2024
|
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
- Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC. During his presentation, titled “Vaccine Induction of Broadly-Specific Antibody and T Cell Responses to Combat SARS-CoV-2 Variation”, Dr. Newman described GeoVax's development program for GEO-CM04S1.
- 04/04/2024
|
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
- ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024.
- 03/28/2024
|
GeoVax to Present at the 36th Annual Roth Conference
- ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024.
- 03/12/2024
|
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
- Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company's MVA-based vaccines, with the release of its first lot of GEO-CM04S1 (next-generation Covid-19 vaccine) produced with a commercial manufacturing platform. This milestone marks the successful completion of the transfer and scale-up of manufacturing from the research-focused Center for Biomedicine & Genetics at City of Hope (Duarte, CA) to the experienced CDMO ABL Europe (a subsidiary of Oxford Biomedica), the Company's cGMP (current Good Manufacturing Procedures) manufacturing partner.
- 03/06/2024
|
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
- 03/01/2024
|
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
- Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin ® , targeting advanced head and neck cancer
- 02/29/2024
|
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
- GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2023 financial results on Thursday, February 29, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m.
- 02/22/2024
|
GeoVax to Present at the 2024 BIO CEO & Investor Conference
- ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
- 02/19/2024
|
GeoVax Announces Multiple Patent Issuances and Allowances
- Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines
- 02/13/2024
|
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
- Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced positive initial safety and immune response findings from its Phase 2 clinical trial at one month following administration of its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine (ClinicalTrials.gov Identifier: NCT04639466 ), was fully enrolled at the end of Sept 2023.
- 02/06/2024
|
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
- ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), at a ratio of 1-for-15. The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The reverse stock split was approved by the Company's stockholders at a meeting held January 16, 2024.
- 01/29/2024
|
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
- Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D.
- 01/08/2024
|
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
- Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer. Kelly McKee, MD, MPH, GeoVax's Chief Medical Officer, stated, “Completion of this trial will be a significant milestone in our Gedeptin clinical development program.
- 01/04/2024
|
GeoVax Announces Issuance of Malaria Vaccine Patent
- Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company's patent application No.
- 01/03/2024
|
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
- ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024.
- 12/27/2023
|
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
- ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax's development of a vaccine against SARS-CoV-2 (COVID-19). The amendment expands GeoVax's commercial license to include Mpox and smallpox as additional indications.
- 12/19/2023
|
GeoVax to Participate in Upcoming December Investor Events
- ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its senior management will participate in two upcoming investor events:
- 11/29/2023
|
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
- Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from the active development program for its next-generation COVID-19 vaccine (GEO-CM04S1), including Phase 2 clinical trial data. The data include some of which was recently published in the journal Vaccines and can be accessed here: GEO-CM04S1 Publication.
- 11/28/2023
|
Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
- Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine. The data were presented during the Vaccines Summit 2023 conference, being held in Boston, MA on November 13-15, 2023.
- 11/14/2023
|
GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript
- 11/08/2023
|
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
- Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C.
- 09/12/2023
|
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will present a company overview and host investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.
- 08/31/2023
|
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
- Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs
- 08/29/2023
|
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
- GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report second quarter 2023 financial results on Wednesday, August 9, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results.
- 07/26/2023
|
GeoVax Labs, Inc. (GOVX) Q1 2023 Earnings Call Transcript
- GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Gabby DeGravina - Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright Kumar Raja - Roth Capital Robert LeBoyer - Noble Capital Markets Operator Good afternoon and welcome everyone to the GeoVax First Quarter 2023 Corporate Update Call.
- 05/07/2023
|
GeoVax Labs, Inc. (GOVX) Q4 2022 Earnings Call Transcript
- GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President & CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer Mark Newman - Chief Scientific Officer John Sharkey - Head of Business Development Conference Call Participants Jason Kolbert - Dawson James Securities Vernon Bernardino - H.C. Wainwright & Co. Joanne Lee - Maxim Group Robert LeBoyer - Noble Capital Kumar Raja - ROTH Capital Jeffrey Kraws - Crystal Research Associates Operator Good afternoon and welcome everyone to the GeoVax Fourth Quarter and Full Year 2022 Corporate Update Call.
- 03/23/2023
|
Penny Stocks To Buy Now? 5 To Watch After News This Week
- Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?
- 02/08/2023
|
Why Investing in Penny Stocks Could Be Worth It
- Are penny stocks worth investing in? The post Why Investing in Penny Stocks Could Be Worth It appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/26/2023
|
Why Is GeoVax (NASDAQ:GOVX) Stock Up 80% Today?
- Shares of GeoVax (NASDAQ: GOVX ) are shooting to the top of today's trending ticker list. That's as GOVX stock is higher by about 60% so far on Wednesday.
- 01/25/2023
|
The Do's and Don'ts of Penny Stocks Investing for New Investors
- Understand these tips for investing in penny stocks The post The Do's and Don'ts of Penny Stocks Investing for New Investors appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/19/2022
|
GeoVax Labs, Inc. (GOVX) Q3 2022 Earnings Call Transcript
- GeoVax Labs, Inc. (NASDAQ:GOVX ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer John Sharkey - Head, Business Development Kelly McKee - Chief Medical Officer Conference Call Participants Jeffrey Kraws - Crystal Research Associates Robert LeBoyer - Noble Capital Operator Good afternoon and welcome everyone to the GeoVax Third Quarter 2022 Corporate Update Call. My name is Ralph and I will facilitate today's call.
- 11/09/2022
|
Trending Penny Stocks You Need to Watch This Week
- Here's what you need to know about trading penny stocks today The post Trending Penny Stocks You Need to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/12/2022
|
How to Find Penny Stocks to Buy This Month, 3 Tips
- Use these strategies for investing in penny stocks in 2022 The post How to Find Penny Stocks to Buy This Month, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/11/2022
|
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
- Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.
- 08/17/2022
|
GeoVax Labs Stock Has a Lot More Than Hype Behind Its Recent Surge
- GeoVax Labs (NASDAQ: GOVX ) stock has gone parabolic and it's easy to see why. As the extent of the 2022 monkeypox outbreak keeps getting worse, this virus continues to be at the top of the headlines.
- 08/09/2022
|
GeoVax: Possible Vaccine Advancements In 2 Big Indications
- GeoVax has multiple routes to go in terms of Covid-19 vaccine development; use of GEO-CM04S1 for Covid-19 in immunocompromised patients and as booster, plus GEO-CM02 as pan-coronavirus vaccine. GeoVax has the potential to possibly advance GEO-CM04S1 as a preventative Monkeypox vaccine. Successful prevention of Monkeypox in non-human primate models has been shown in peer-reviewed journal using MVA.
- 08/08/2022
|
GeoVax Labs, Inc. (GOVX) CEO David A. Dodd on Q2 2022 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants David Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John Sharkey – Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Jeff Kraws - Crystal Research Kumarguru Raja - Brookline Capital Markets Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2022 Corporate Update Call. I'm Andrew with Chorus Call and will facilitate today's call.
- 08/03/2022
|
Geovax Labs (GOVX) Stock: Why It Climbed 42.86% Today
- The stock price of Geovax Labs (GOVX) surged by 42.86% today. This is why.
- 08/01/2022
|
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
- Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency orders related to monkeypox. Several related names rallied in pre-market trading today and are still up since the market opened this morning.
- 08/01/2022
|
Top Tricks for Trading Penny Stocks Right Now, 3 Tips
- Check these tips out for your penny stocks buy list right now The post Top Tricks for Trading Penny Stocks Right Now, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/30/2022
|
Hot Penny Stocks to Watch Before Market Open on July 29th
- Here's what you need to know about buying penny stocks on July 29th The post Hot Penny Stocks to Watch Before Market Open on July 29th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/29/2022
|
What to Know About Buying Penny Stocks on July 27th
- Here's what you need to know about buying penny stocks on July 27th The post What to Know About Buying Penny Stocks on July 27th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/27/2022
|
What to Know About Buying Penny Stocks on July 26th
- Here's what you need to know about trading penny stocks on July 26th The post What to Know About Buying Penny Stocks on July 26th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/26/2022
|
Hot Penny Stocks To Watch As Monkeypox Gets WHO GHE Designation
- If you thought monkeypox was a fad, you might want to reconsider.
- 07/25/2022
|
Hot Penny Stocks to Buy in July? Check These 3 Out
- Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in July?
- 06/22/2022
|
5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now?
- Penny stocks are red hot right now if you know where to… The post 5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/17/2022
|
Two Pharma Companies That Will Profit From The MonkeyPox Outbreak
- The monkeypox outbreak has affected 780 people since identified on May 13, 2022. Vaccines are key to curtailing the spread of Monekey Pox. Two pharma companies, Geovax Labs Inc. and Emergent Biosolutions, have already benefited from the outbreak.
- 06/12/2022
|
What to Know About Buying Penny Stocks on June 2nd
- Here's what you need to know about trading penny stocks on June 2nd The post What to Know About Buying Penny Stocks on June 2nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/02/2022
|
Top Penny Stocks To Watch As Monkeypox Cases Rise
- Monkeypox penny stocks to watch right now The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/01/2022
|
Top Penny Stocks to Watch After a Bullish Trading Day
- Here are three penny stocks to watch after today's bullish session The post Top Penny Stocks to Watch After a Bullish Trading Day appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/26/2022
|
3 Penny Stocks Worth Watching This Week
- Are these penny stocks on your list right now? The post 3 Penny Stocks Worth Watching This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/24/2022
|
7 Monkeypox Stocks to Watch Right Now
- Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.
- 05/24/2022
|
Top Penny Stocks to Buy Now? 3 to Watch as May Ends
- Check these three penny stocks for your watchlist The post Top Penny Stocks to Buy Now? 3 to Watch as May Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/23/2022
|
Penny Stocks To Buy Now? Hot Monkeypox Stocks To Watch Today
- Monkeypox stocks to watch today. The post Penny Stocks To Buy Now?
- 05/20/2022
|
GeoVax Labs, Inc (GOVX) CEO David A. Dodd on Q1 2022 Results - Earnings Call Transcript - Earnings Call Transcript
- GeoVax Labs, Inc (NASDAQ:GOVX ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants David A. Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John W.
- 04/27/2022
|
3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120%
- Why these 3 penny stocks are climbing today The post 3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/26/2022
|
GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate
- The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.
- 04/26/2022
|
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2021 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2021 Results - Earnings Call Transcript
- 03/09/2022
|
GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
- GOVX is uniquely positioned with its Phase 2 COVID-19 vaccine candidate for immunocompromised individuals. It has also started a Phase 2 trial as a booster vaccine for the general population. In addition to its GEO/COH04S1 and GEO-CM02 COVID-19 vaccine candidates, it has clinical trials on HIV and early stage candidates for a variety of infectious diseases, funded through non-dilutive sources.
- 12/27/2021
|
GeoVax Initiates Phase 2 Trial For COVID-19 Vaccine Booster
- GeoVax Labs Inc (NASDAQ: GOVX) initiated vaccine dosing in the Phase 2 portion of its Phase 1/2 trial of COH04S1 COVID-19 vaccine to target both the spike (S) and nucleocapsid (N) proteins. The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy adult individuals aged 18 to 55 who had not been previously infected with SARS-CoV-2.
- 12/15/2021
|
GeoVax initiates Phase 2 clinical trial for its experimental COVID-19 booster
- Shares of GeoVax Labs Inc. GOVX, -1.76% were down 1.4% in trading on Wednesday after the company said it began a Phase 2 clinical trial for its COVID-19 booster candidate.
- 12/15/2021
|
Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets
- Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?
- 11/26/2021
|
Geovax Labs (GOVX) Stock: Why The Price Surged Today
- The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 35% pre-market today. This is why it happened.
- 11/26/2021
|
Geovax Labs (GOVX) Stock: Why The Price Jumped Today
- The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 14% during intraday trading today. This is why it happened.
- 11/16/2021
|
GeoVax Labs, Inc. (NASDAQ: GOVX) Receives Notice of Allowance For Cancer Vaccine Patent
- GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company developing human immunotherapies and vaccines…
- 11/16/2021
|
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q3 2021 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q3 2021 Results - Earnings Call Transcript
- 11/11/2021
|
GOVX Stock: Why It Increased Today
- The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 3% during intraday trading today. This is why it happened.
- 09/29/2021
|
Geovax Labs Shares Increased 32.79%: Why It Happened
- The shares of Geovax Labs Inc (NASDAQ: GOVX) increased 32.79% in the previous trading session. This is why it happened.
- 08/22/2021
|
GOVX Stock: Why GeoVax Shares Are Skyrocketing Today
- Geovax Labs (GOVX) stock is soaring higher on Friday after the company presented COVID-19 vaccine data at a recent conference. The post GOVX Stock: Why GeoVax Shares Are Skyrocketing Today appeared first on InvestorPlace.
- 08/20/2021
|
Why Geovax Labs Shares Are Soaring Today
- Geovax Labs Inc (NASDAQ: GOVX) is trading significantly higher Friday after the company announced it presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Society of Medicine General Assembly. Using its novel Modified Virus Ankara-Virus Like Particle (GV-MVA-VLP) platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple structural and nonstructural proteins from the target pathogen.
- 08/20/2021
|
GeoVax Shares Increase Over 70% Pre-Market: Why It Happened
- The shares of GeoVax Labs, Inc. (Nasdaq: GOVX) increased by over 70% pre-market. This is why it happened.
- 08/20/2021
|
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q2 2021 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
GOVX Stock Increases Over 10% Intraday: Why It Happened
- The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 10% during intraday trading. This is why it happened.
- 07/22/2021
|
GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit
- Atlanta, Georgia--(Newsfile Corp. - May 11, 2021) - GeoVax Labs, Inc. (NASDAQ: GOVX) today announced that David Dodd, Chairman & CEO will be attending the Q2 Virtual Investor Summit. Event Q2 Investor Summit Date May 17-18th, 2021 Presentation May 18th at 8:45 AM ET
- 05/11/2021
|
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q1 2021 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript
- 03/24/2021
|
GeoVax Spikes 80% On COVID-19 Research Grant Report
- GeoVax (NASDAQ: GOVX) shares are trading sharply higher on Monday after the company announced it was awarded an NIH grant to advance its COVID-19 vaccine development. GeoVax is a U.S.-based clinical-stage biotechnology company.
- 01/11/2021
|
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript
- GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript
- 11/08/2020
|
GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript
- GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript
- 11/06/2020
|
GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update
- Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs
- 11/05/2020
|
GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update
- Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time
- 10/30/2020
|
GeoVax CEO David Dodd to Participate in Virtual Webinar Hosted by Outsourced Pharma
- ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announces that CEO and Chairman David Dodd will participate in an upcoming virtual webinar titled, “What COVID-19 Vaccines Teach Us About All Tech Transfers.” Sponsored by Outsourced Pharma (www.outsourcedpharma.com), the event will be held on Wednesday, November 4, 2020 at 2:00pm ET. Discussion topics include the lessons learned and best practices from the COVID-19 vaccine efforts that can be applied to technology transfers.
- 10/28/2020
|
GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development
- ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax's development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAID's patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.
- 10/26/2020
|
Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources
- Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources
- 10/20/2020
|
Remdesivir has ‘little or no effect’ in reducing coronavirus deaths, WHO says
- A study coordinated by the World Health Organization has indicated that remdesivir, along with three other potential drug treatments for the coronavirus, has "little or no effect" on death rates among hospitalized patients.
- 10/16/2020
|
Majoration pour vie autonome
- Incessible et insaisissable, la majoration pour la vie autonome (MVA) est une aide financière permettant le maintien à domicile d'une personne handicapée. Depuis le 1er décembre 2019, l’ancien complément
- 10/09/2020
|
Audit Faults MVA For Suspicious Addresses, 'Points' Not Applied
- The department issued driver's licenses to thousands who used questionable addresses, also failing to properly track driving infractions.
- 09/30/2020
|
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology - ResearchAndMarkets.com
|
Engagement with anti-vaccine Facebook posts trebles in one month
- Exclusive: Guardian analysis prompts calls for new drive to combat conspiracy theories
- 09/19/2020
|
Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials
- Interim data from a Phase 2 clinical trial of LY-CoV555 shows a reduction in the rate of hospitalization in patients treated with the antibody.
- 09/16/2020
|
Plasma Treatment For COVID-19 Unlikely To Be 'Home Run,' Says Ex-FDA Commissioner
- The FDA granted emergency authorization of convalescent plasma to treat hospitalized COVID-19 patients on Sunday, and this could be helpful in treating sick people, former...
- 08/24/2020
|
COVID-19 era highlights U.S. 'black hole' compensation fund for pandemic vaccine injuries
- COVID-19 era highlights U.S. 'black hole' compensation fund for pandemic vaccine injuries
- 08/21/2020
|
Coronavirus update: U.S. case tally climbs above 4.8 million as Trump contradicts health experts to claim virus will ‘go away’
- The number of confirmed cases of the coronavirus that causes COVID-19 in the U.S. rose above 4.8 million on Thursday, a day after President Donald Trump...
- 08/06/2020
|
NDPHC: Bridging the electricity gap - Vanguard News
- Many Nigerians have come to the conclusion that inadequate electricity supply in the country is one of the factors inhibiting national growth.
- 08/02/2020
|
Shiv Sena ‘betrayed’ poll mandate for Maharashtra CM post: Prakash Javadekar
- Javadekar said the government isconsidering merging film units of the Information and Broadcasting Ministry like
Children's Film Society and Films Division into one entity so that existing resources can be utilised effectively.
- 07/31/2020
|
MVA scraps pension scheme meant for the prisoners booked under MISA
- In another reversal of the decisions taken by the previous Fadnavis government, Maharashtra Vikas Aghadi (MVA) government on Friday scrapped the pension scheme meant for the...
- 07/31/2020
|
Uddhav Thackeray shows who’s boss
- The Maharashtra chief minister’s firm stance on several issues has surprised allies Congress and NCP
- 07/30/2020
|
PLN segera tuntaskan pembangunan lima gardu induk di Lombok
- PT PLN (Persero) Unit Induk Pembangunan Nusa Tenggara (UIP Nusra) segera menuntaskan pembangunan lima gardu induk untuk memperkuat keandalan sistem ...
- 07/23/2020
|
GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research
- ATLANTA, GA, June 10, 2020 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious.
- 06/10/2020
|
GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market
- ATLANTA, GA, June 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, is pleased to announce that it has been approved to trade on the OTCQB Venture Market as of June 4, 2020. "I would like to thank our shareholders for their support as GeoVax worked toward this important milestone," stated David Dodd, President & CEO of GeoVax.
- 06/04/2020
|
GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update
- ATLANTA, GA, May 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2020 and provided an update on its corporate development progress. From here, we will narrow to one vaccine candidate based on the safety, immunogenicity and protective efficacy of our PreMaster Seed Viruses observed when we conduct our animal studies.
- 05/06/2020
|
GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development
- ATLANTA, GA, April 30, 2020 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious.
- 04/30/2020
|
GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act
- ATLANTA, GA, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today commented on the passage of the Coronavirus Aid, Relief, and Economic Security Act (CARES ACT), which was signed into law by President Trump on March 27, 2020. Among the many provisions of this unprecedented $2 trillion economic stimulus bill, $27 billion of emergency funding is appropriated for the “Public Health and Social Services Emergency Fund” to prevent, prepare for, and respond to the current coronavirus pandemic, including the development of countermeasures and vaccines. GeoVax is using itsGV-MVA-VLPTM vaccine platform and expertise to develop vaccine candidates using genetic sequences from SARS-CoV-2, the virus responsible for the ongoing COVID-19 outbreak.
- 03/30/2020
|
GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update
- ATLANTA, GA, March 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2019 and provided an update on its corporate development progress. This was combined with tough capital restructuring decisions that, while painful at the time, have now resulted in GeoVax being better positioned for future financing efforts in support of our programs and increasing shareholder value.
- 03/25/2020
|
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
- ATLANTA, GA, March 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China.
- 03/18/2020
|
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
- ATLANTA, GA, March 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. The update was given by GeoVax’s Chief Scientific Officer, Farshad Guirakhoo, PhD, during his presentation on emerging infectious diseases entitled “Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform” at the World Immunotherapy Congress in San Diego, California.
- 03/04/2020
|
Maharashtra govt to give 5% quota to backward Muslim students
- Maharashtra's MVA government plans to bring in a law to provide five percent reservations to backward Muslims in government education institutions.
- 02/29/2020
|
GeoVax to Present at World Immunotherapy Congress 2020
- ATLANTA, GA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will be a featured speaker at the World Immunotherapy Congress, being held March 2-4, 2020 in San Diego, California. The first, on March 2, is entitled Utilizing a Live Modified Vaccinia Ankara Virus to Deliver Tumor Associated Antigen MUC1 on the Surface of Virus Like Particles and will focus on GeoVax’s efforts toward development of cancer immunotherapies. During his second presentation on March 4, entitled Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform, Dr. Guirakhoo will discuss the Company’s design of MVA-VLP and non-VLP vaccines for Zika, Ebola, Marburg and Lassa fever vaccines, as well as results from efficacy studies in animal challenge models.
- 02/27/2020
|
Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
- ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today commented on the recent discontinuance of the HVTN 702 clinical trial. On February 3, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced that it has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine.
- 02/06/2020
|
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
- ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today commented on the recent discontinuance of the HVTN 702 clinical trial. On February 3, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced that it has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine.
- 02/06/2020
|
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
- ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus (known as 2019-nCoV). Under the collaboration, GeoVax will use its MVA-VLP vaccine platform and expertise to design and construct the vaccine candidate using genetic sequences from the ongoing coronavirus outbreak originating in Wuhan, China.
- 01/27/2020
|
GeoVax Announces Reverse Stock Split
- 1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX).
- 01/23/2020
|
GeoVax to Present at World Vaccine & Immunotherapy Conference
- Two Separate Presentations to Focus on the Company’s Infectious Disease Vaccines and Cancer Immunotherapy Programs ATLANTA, GA, Dec. 03, 2019 -- via NEWMEDIAWIRE -- GeoVax.
- 12/03/2019
|
GeoVax Observes 2019 World AIDS Day
- Developing Multiple Strategies Toward Ending the HIV/AIDS Epidemic ATLANTA, GA, Dec. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology.
- 12/02/2019
|
GeoVax to Present at Vaccines R&D Conference
- Presentation to Focus on the Company’s MVA-VLP Platform for Safe and Effective Vaccines for Infectious Diseases and Cancer ATLANTA, GA, Nov. 14, 2019 -- via NEWMEDIAWIRE --.
- 11/14/2019
|
GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure
- The proposed clinical trial will enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy (ART). The therapeutic regimen to be tested involves a combination of vaccinations (DNA priming and MVA boosting), administration of broadly neutralizing antibodies (bNAbs) and a Toll-like receptor 9 (TLR9) agonist. GeoVax will provide its novel boost component (MVA62B) for use in the studies.
- 11/13/2019
|
GOVX: Third Quarter 2019 Results and Update
- OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) filed its third quarter 2019 10-Q and issued the accompanying press release on November 7, 2019 providing an operational and financial update on the company’s performance. During the third quarter and to date GeoVax gave several presentations related to the Lassa fever, HIV and Marburg programs, issued additional shares to satisfy convertible preferred
- 11/11/2019
|
GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update
- The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA / ACCESSWIRE / November 7, 2019 / GeoVax Labs, Inc. (OTCQB:GOVX), ...
- 11/07/2019
|
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
- On October 18, 2019, AGT announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, a lentiviral vector-based gene therapy. Upon clearance by the FDA, this IND will allow AGT to initiate a Phase 1 clinical trial that will investigate the safety of AGT103-T in humans, measure key biomarkers, and explore surrogate markers of efficacy. AGT expects to begin recruiting patients for the Phase 1 study in January.
- 10/24/2019
|
Ketersediaan listrik menjadi penentu pembangunan industri nasional
- Pemerintah saat ini tengah giat-giatnya mendorong pengusaha untuk berinvestasi sebagai upaya memacu pertumbuhan ekonomi, namun untuk mewujudkannya ...
- 06/25/2019
|
